UNLABELLED: The aim of this study was the detection of circulating tumor cells (CTC) in three tumor types of epithelial origin. PATIENTS AND METHODS: Four hundred and thirty-eight patients with breast cancer (56.2% localized and 43.8% metastatic), 195 with colorectal tumors (84.1% localized and 15.9% metastatic) and 50 with prostate cancer (52% localized and 48% metastatic) took part in this study. CTC quantification was performed using the CellSpotter Analyzer (Veridex LLC). RESULTS: 31.5% of patients with cancer had > or =2 CTCs/7.5 mL but none of the healthy volunteers were above this level (p<0.001). Among patients with metastatic disease, 62.3% of them had > or =2 CTCs/7.5 mL but only 14.0% of those with localized disease were above this level (p<0.001). The presence of CTCs were correlated to stage in the three studied tumor types and no differences in the number of cells were found between them. CONCLUSION: The presence of more than 2 CTCs/7.5 ml is a frequent event in metastatic cases. In particular, patients with localized disease who have more than 2 CTCs/7.5 ml should be carefully studied to determine the possible prognostic and predictive value of this finding.
UNLABELLED: The aim of this study was the detection of circulating tumor cells (CTC) in three tumor types of epithelial origin. PATIENTS AND METHODS: Four hundred and thirty-eight patients with breast cancer (56.2% localized and 43.8% metastatic), 195 with colorectal tumors (84.1% localized and 15.9% metastatic) and 50 with prostate cancer (52% localized and 48% metastatic) took part in this study. CTC quantification was performed using the CellSpotter Analyzer (Veridex LLC). RESULTS: 31.5% of patients with cancer had > or =2 CTCs/7.5 mL but none of the healthy volunteers were above this level (p<0.001). Among patients with metastatic disease, 62.3% of them had > or =2 CTCs/7.5 mL but only 14.0% of those with localized disease were above this level (p<0.001). The presence of CTCs were correlated to stage in the three studied tumor types and no differences in the number of cells were found between them. CONCLUSION: The presence of more than 2 CTCs/7.5 ml is a frequent event in metastatic cases. In particular, patients with localized disease who have more than 2 CTCs/7.5 ml should be carefully studied to determine the possible prognostic and predictive value of this finding.
Authors: Ajjai Alva; Susan Slovin; Stephanie Daignault; Michael Carducci; Robert Dipaola; Ken Pienta; David Agus; Kathleen Cooney; Alice Chen; David C Smith; Maha Hussain Journal: Invest New Drugs Date: 2010-11-04 Impact factor: 3.850
Authors: Ronald Rodriguez; Shawn E Lupold; Ping Wu; Lori J Sokoll; Tarana A Kudrolli; Wasim H Chowdhury; Rong Ma; Minzhi M Liu Journal: Prostate Date: 2014-07-25 Impact factor: 4.104
Authors: Paola Gazzaniga; Walter Gianni; Cristina Raimondi; Angela Gradilone; Giuseppe Lo Russo; Flavia Longo; Orietta Gandini; Silverio Tomao; Luigi Frati Journal: Tumour Biol Date: 2013-03-29
Authors: Antonio Giordano; Brian L Egleston; David Hajage; Joseph Bland; Gabriel N Hortobagyi; James M Reuben; Jean-Yves Pierga; Massimo Cristofanilli; Francois-Clement Bidard Journal: Clin Cancer Res Date: 2013-01-22 Impact factor: 12.531
Authors: Meng Zhao; Xueliang Pan; Rachel Layman; Maryam B Lustberg; Ewa Mrozek; Erin R Macrae; Robert Wesolowski; Sarah Carothers; Shannon Puhalla; Charles L Shapiro; Bhuvaneswari Ramaswamy Journal: Invest New Drugs Date: 2014-06-05 Impact factor: 3.850